Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
296
-
Total 13F shares, excl. options
-
47.9M
-
Shares change
-
+8.59M
-
Total reported value, excl. options
-
$4B
-
Value change
-
+$725M
-
Put/Call ratio
-
1.05
-
Number of buys
-
153
-
Number of sells
-
-112
-
Price
-
$83.64
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2020
355 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q3 2020.
CRISPR Therapeutics AG - Common Stock (CRSP) has 296 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.9M shares
of 86M outstanding shares and own 55.66% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.46M shares), Capital International Investors (7.39M shares), Nikko Asset Management Americas, Inc. (3.7M shares), Versant Venture Management, LLC (3.63M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.63M shares), NEA Management Company, LLC (1.59M shares), PERCEPTIVE ADVISORS LLC (1.34M shares), WADDELL & REED FINANCIAL INC (1.31M shares), BlackRock Inc. (1.15M shares), and Bellevue Group AG (949K shares).
This table shows the top 296 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.